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Abstract
Aims/hypothesis Both visceral and truncal fat have been associated with metabolic disturbances. We aimed to investigate the
associations of several novel metabolic indices, combining anthropometric and lipid measures, and dual-energy x-ray absorpti-
ometry (DXA) measurements of body fat, with incident type 2 diabetes among women and men from the large population-based
Rotterdam Study.
Methods Cox proportional hazards models were used to investigate associations of visceral adiposity index (VAI), lipid accu-
mulation product (LAP), the product of triacylglycerol and glucose (TyG), their formula components and DXA measures with
incident type 2 diabetes. Associations were adjusted for traditional diabetes risk factors.
Results Among 5576 women and 3988 men free of diabetes, 511 women and 388 men developed type 2 diabetes during a
median follow-up of 6.5 years. In adjusted models, the three metabolic indices VAI (per 1 SD naturally log-transformed HR; 95%
CI) (1.49; 1.36, 1.65 in women; 1.37; 1.22, 1.53 in men), LAP (1.35; 1.16, 1.56 in women; 1.19; 1.01, 1.42 in men) and TyG
(1.73; 1.52, 1.98 in women; 1.43; 1.26, 1.62 in men), gynoid fat mass (0.63; 0.45, 0.89) and android to gynoid fat ratio (1.51;
1.16, 1.97) in women were associated with incident type 2 diabetes. BMI (1.45; 1.28, 1.65) was the strongest predictor of type 2
diabetes in men.
Conclusions/interpretation Among women, novel combined metabolic indices were stronger risk markers for type 2 diabetes
than the traditional anthropometric and laboratory measures and were comparable with DXA measures. Neither combined
metabolic indices nor DXA measures were superior to traditional anthropometric and lipid measures in association with type
2 diabetes among men.
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Introduction
The location of fat accumulation in the body, rather than total
fat volume, is increasingly shown to be more important for the
risk of type 2 diabetes [1]. Both visceral adipose tissue (VAT)
and truncal fat depot have been associated with type 2 diabetes
[2–4] and the metabolic syndrome [5, 6].
VAT is a hormonally active component of body fat. The
risk of developing diabetes has been shown to be higher in
individuals with excess visceral adiposity, with [3] or without
[7] manifestations of obesity. Therefore, VAT plays a key role
in the association between adiposity and glucose metabolism
[4, 8–10]. However, traditional anthropometric measures such
as BMI and waist circumference (WC) are not able to distin-
guish VAT from subcutaneous adipose tissue [11].
Furthermore, VAT accounts for an increased cardiometabolic
risk regardless of BMI levels [12]. Truncal fat depot can be
partitioned into upper body (android or central) and lower
body (gynoid or peripheral) areas. High android to gynoid
per cent fat ratio has shown a greater correlation with cardio-
metabolic dysregulation compared with BMI [13]. Among the
elderly, the android fat depot seems to be more closely asso-
ciated with the metabolic syndrome compared with abdominal
visceral fat [5].
Computed tomography (CT) [2, 12] and MRI [3] are the
gold standard measures for quantification of VAT. Dual-
energy x-ray absorptiometry (DXA) is a well-validated imag-
ing method for precise measurement of body fat mass in var-
ious body compartments (i.e. android and gynoid fat) [14].
However, these imaging modalities for assessing adipose tis-
sue distribution are inconvenient and expensive. Recently,
different metabolic indices combining both anthropometric
and lipid measures have been used as estimators of visceral
adiposity dysfunction [15] and lipid overaccumulation [16,
17]. These novel indices, including visceral adiposity index
(VAI), lipid accumulation product (LAP) and the product of
triacylglycerol (TG) and glucose (TyG), have been suggested
as early markers of insulin resistance, mainly in cross-
sectional studies [18–20]. However, the associations of these
novel metabolic indices with incident type 2 diabetes remain
unclear. We therefore studied the associations of different nov-
el metabolic indices and their formula components with inci-
dent type 2 diabetes among women and men from the large
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prospective population-based Rotterdam Study. We further
assessed the associations of truncal fat depot measured by
DXAwith incident type 2 diabetes.
Methods
Study population The study was performed in the framework
of the Rotterdam Study, a prospective population-based co-
hort study carried out in Ommoord, a district of Rotterdam,
the Netherlands. The design of the Rotterdam Study has been
described in more detail elsewhere [21]. The original cohort
(RSI) started in 1989 when all residents within the well-
defined study area aged 55 years or older were invited to
participate, of whom 78% (7983 out of 10,275) accepted.
The first examination of the original cohort (RSI-1) took place
from 1990 to 1993. The cohort has been extended twice (RSII
in 2000 and RSIII in 2006) to include participants who were
45 years or older or who had moved to the study research area.
For all three cohorts of the Rotterdam Study, follow-up exam-
inations were conducted every 3–5 years. The study was ap-
proved according to the Population Screening Act: Rotterdam
Study by the medical ethics committee of the Netherlands
Ministry of Health, Welfare and Sport. All participants pro-
vided written informed consent to take part in the study and
allow investigators to obtain information from their treating
physicians.
The current study was based on data collected during the
third visit of the first cohort (RSI-3; 1997-1999), the first visit
of the second cohort (RSII-1; 2000-2001) and the first visit of
the third cohort (RSIII-1; 2006-2008). From 11,740 individ-
uals in the three visits, diabetes data were available for 10,898
(6241 women and 4657 men). After excluding 1334 prevalent
diabetes cases (665 women and 669 men), 9564 people (5576
women and 3988 men) were included in the analyses of dif-
ferent metabolic indices and incident type 2 diabetes. DXA
body fat measurements were available for 3518 individuals
(2026 women and 1492 men) with available diabetes data at
the fourth visit of the first cohort (RSI-4; 2002-2004) and the
second visit of the second cohort (RSII-2; 2004-2005). After
excluding 556 prevalent diabetes cases (292 women and 264
men) at the time of DXA measurement, 2962 individuals
(1734 women and 1228 men) were included in the analyses
of DXA measures of body fat and incident type 2 diabetes.
Combined metabolic indices Novel metabolic indices com-
bine anthropometric measures such as BMI andWCwith lipid
measures: TG, HDL-cholesterol or fasting plasma glucose
(FPG).
LAP, VAI and TyGwere calculated using published formulae.
LAP was calculated as LAP = (WC − 65) × TG for men and
LAP = (WC − 58) × TG for women [22]. VAI was calculated
as VAI ¼ WC39:68
 þ 1:88 BMIð Þ  TG1:03
  1:31HDL
 
fo r
men and VAI ¼ WC36:58
 þ 1:89 BMIð Þ  TG0:81
  1:52HDL
 
for women [15]. In both formulae, TG and HDL-cholesterol
levels are expressed in mmol/l, WC in cm and BMI in kg/m2.
The TyG index was calculated as Loge TG FPG2
 
, where both
TG and FPG are expressed in mg/dl [18, 20].
DXA measurements of body fat Body composition was
assessed using DXA. A Prodigy total body-fat beam densi-
tometer (GE Lunar, Madison, WI, USA) was used to perform
whole-body DXA scans [21]. Total body weight (g) was di-
vided into bone mineral content, lean mass and fat mass. In
addition, fat mass of the android and gynoid body regions was
analysed. Total per cent fat mass, per cent android fat and per
cent gynoid fat were calculated as percentages of total body
weight. The ratio of per cent android to gynoid fat mass was
also calculated.
Ascertainment of type 2 diabetes mellitus Participants were
followed from the date of their baseline visit onwards. Cases
of type 2 diabetes were ascertained through active follow-up
using general practitioners’ records, hospital discharge letters,
pharmacy data and glucose measurements from study visits
which took place approximately every 4 years [23]. In the
Rotterdam Study, type 2 diabetes ascertainment was done in
the sameway for all individuals, avoiding substantial potential
for misclassification or ascertainment bias. According to the
current WHO guidelines, type 2 diabetes was defined as FPG
≥7.0 mmol/l, non-FPG ≥11.1 mmol/l (when fasting samples
were unavailable) or use of blood glucose-lowering medica-
tion [24]. Information regarding the use of blood glucose-
lowering medication was derived from both structured home
interviews and linkage to pharmacy dispensing records. At
baseline, more than 95% of the Rotterdam Study population
was covered by the pharmacies in the study area. All potential
events of type 2 diabetes were independently adjudicated by
two study physicians. In case of disagreement, consensus was
sought with an endocrinologist. Follow-up data were com-
plete until 1 January 2012 [25].
Assessment of covariates Height and weight were measured
with the participants standing without shoes and heavy outer
garments. Waist circumference was measured at the level mid-
way between the lower rib margin and the iliac crest with
participants in a standing position without heavy outer gar-
ments and with emptied pockets, breathing out gently. Blood
pressure was measured twice at the right brachial artery with a
random-zero sphygmomanometer with the participant in a
sitting position, and the mean of two consecutive measure-
ments was used. Insulin, glucose, HDL-cholesterol, and TG
were measured on the COBAS 8000 Modular Analyzer
(Roche Diagnostics GmbH). HOMA-IR and HOMA-B were
calculated as described previously [26]. TG levels were not
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available at the same visit as DXA measures (RSI-4) and thus
they were taken from the closest previous visit (RSI-3). The
corresponding interassay coefficients of variation are the fol-
lowing: insulin <8%, glucose <1.4% and lipids <2.1%.
Information on medication use and tobacco smoking behav-
iour was collected by trained research assistants via
computerised questionnaires during home visits. Smoking
was classified as current vs non-current smokers. History of
cardiovascular disease (CVD) was defined as a history of cor-
onary heart disease (myocardial infarction, revascularisation,
coronary artery bypass graft surgery or percutaneous coronary
intervention) or stroke and was verified from the medical re-
cords of the general practitioners.
Statistical analysis Considering sex differences in fat distribu-
tion and that the formulae of metabolic indices differ by sex,
all analyses were performed among women and men separate-
ly. Descriptive characteristics were presented as means ± SD
for continuous variables, and numbers (percentages) for di-
chotomous variables. One-way ANOVA for continuous vari-
ables and the χ2 test for categorical variables were used to
compare general characteristics between women and men as
well as between participants with and without DXA measure-
ments. Markers with a right-skewed distribution (insulin,
glucose, HDL-cholesterol, TG, VAI, LAP, per cent android
fat, per cent gynoid fat, android to gynoid fat ratio and per
cent total fat mass) were transformed to the natural logarithmic
scale.
Cox proportional hazards models were used to investi-
gate associations of different combined metabolic indices
(VAI, LAP, TyG), the anthropometric (BMI, WC) or labo-
ratory components (inverse HDL-cholesterol, TG) includ-
ed in their formulae, as well as DXA measurements of
body fat (android, gynoid, total fat mass, the ratio of per
cent android to gynoid fat mass) with incident type 2 dia-
betes. Inverse HDL-cholesterol was used to facilitate easier
comparison between the estimates. The proportional haz-
ards assumption of the Cox model was checked by visual
inspection of log minus log plots and by performing a test
for heterogeneity of the exposure over time. There was no
evidence of violation of the proportionality assumption in
any of the models (p value for time-dependent interaction
terms >0.05). The first model was adjusted for age and
cohort. The second model was additionally adjusted for
BMI. The third model was additionally adjusted for systol-
ic BP, hypertension medication, smoking and prevalent
CVD. The fourth model was additionally adjusted for
HDL-cholesterol, TG and serum lipid-reducing agents. In
the fifth model, FPG was added. As glucose measurement
is a means to diagnose type 2 diabetes, model 5 should be
considered a conservative model. For each novel lipid in-
dex, the covariates that were already in the index formula
were excluded from the multivariable-adjusted model.
To check whether the association of different markers with
incident diabetes differed by obesity status, the analyses were
further stratified based on a BMI cut-off of 30 kg/m2 and
performed among non-obese (BMI <30 kg/m2) and obese
(BMI ≥30 kg/m2) individuals. The p value is derived from
the z score calculated from the ratio between the difference
of the two estimates and the SE of the difference [27]. The p
value indicates whether the difference between the estimates is
significant. To compare the estimates between women and
men, an interaction test was applied to model 4 (analyses of
the total population).
Multiple imputation procedure was performed (five impu-
tations) to impute missing data for covariates. All analyses
were conducted using IBM SPSS software, version 21
(IBM, Armonk, NY, USA). A p value below 0.05 was con-
sidered statistically significant.
Results
Metabolic indices and incident type 2 diabetes Baseline char-
acteristics of 5576 women and 3988 men included in the study
are shown in Table 1. Women were older, had lower levels of
systolic BP and glucose but higher levels of total cholesterol. A
larger proportion of women were treated for hypertension. CVD
was more prevalent among men, and a larger proportion of men
were receiving lipid-reducing agents or were current smokers.
BMI, HDL-cholesterol, TG and VAI were higher in women,
whereas WC, LAP and TyG were higher in men (Table 1).
The correlation coefficients for metabolic indices in rela-
tion to glycaemic indices are shown in ESM Table 1. For both
women and men, the correlation coefficients for VAI, LAP
and TyG ranged between 0.43 and 0.57 for HOMA-IR and
between 0.04 and 0.28 for HOMA-B. The correlation coeffi-
cients for different visceral fat indices in relation to HOMA-IR
were overall larger among women compared with men, albeit
not statistically significantly.
During a median follow-up of 6.5 years (maximum
14.7 years) 899 cases of incident type 2 diabetes were identi-
fied (511 women and 388 men). All indices were significantly
associated with the risk of type 2 diabetes in age-adjusted
models (model 1). In the multivariable-adjusted model (model
4), TyG showed the largest association with type 2 diabetes in
both women (per 1 SD HR; 95% CI) (1.73; 1.52, 1.98) and in
men (1.43; 1.26, 1.62). Other markers that remained signifi-
cantly associated with incident type 2 diabetes in both sexes in
the multivariable-adjusted model were BMI (1.37; 1.26, 1.49
in women and 1.45; 1.28, 1.65 in men), inverse HDL-
cholesterol (per 1 SD naturally log-transformed HR; 95%
CI) (1.29; 1.14, 1.46 in women and 1.32; 1.14, 1.52 in men),
VAI (1.49; 1.36, 1.65 in women and 1.37; 1.22, 1.53 in men)
and LAP (1.35; 1.16, 1.56 in women and 1.19; 1.01, 1.42 in
men). WC (1.24; 1.07, 1.45) and TG (1.24; 1.10, 1.39)
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remained strongly associated with the risk of type 2 diabetes
only in women (Table 2). Associations of metabolic indices
with diabetes were overall larger among women compared
with men. However, the difference of the estimates between
women and men was statistically significant only for TyG
(Table 2).
After additionally adjusting for FPG (model 5), only BMI
(1.27; 1.17, 1.38 for women and 1.25; 1.09, 1.43 for men),
inverse HDL-cholesterol (1.29; 1.14, 1.47 for women and
1.41; 1.22, 1.63 for men) and VAI (1.29; 1.17, 1.43 for women
and 1.23; 1.09, 1.38 for men) remained significantly associat-
ed with the risk of type 2 diabetes in both sexes (Table 2).
In the analyses stratified for obesity status, in the
multivariable-adjusted model (model 4), BMI, inverse HDL-
cholesterol, VAI and TyG remained significantly associated
with incident diabetes, regardless of obesity status. While
LAP was significantly associated with incident diabetes
among non-obese women and men, WC and TG remained
strongly associated with the risk of type 2 diabetes only in
non-obese women. Overall, the tendency for the associations
of visceral fat indices with diabetes was stronger among non-
obese individuals (ESM Table 2).
DXA measurements of body fat and incident type 2 diabetes
Android fat, gynoid fat and per cent total fat mass were higher
in women, whereas the ratio of per cent android to gynoid fat
was higher inmen (Table 1). Complete baseline characteristics
of 1770 women and 1258 men included in the analyses of
DXA measurements and type 2 diabetes are presented in
ESM Table 3.
Among 1770 women and 1258 men in the DXA measure-
ment analyses, 185 women and 137 men developed type 2 dia-
betes during amedian follow-up of 8 years (maximum 10 years).
Per cent gynoid fat (per 1 SD naturally log-transformed HR;
95% CI) (0.63; 0.45, 0.89) and the ratio of per cent android to
gynoid fat (1.51; 1.16, 1.97) remained significantly associated
with incident type 2 diabetes in the multivariable-adjusted model
(model 4) only in women (Table 3).
Table 1 Baseline characteristics
of study participants (N = 9564) Characteristic Women (n=5576) Men (n=3988) p value
Age, years 65.1 ± 10.3 64.3 ± 9.5 <0.001
Systolic BP, mmHg 136.2 ± 21.6 138.6 ± 20.2 <0.001
Treatment for hypertension 1225 (22.0) 786 (19.7) 0.011
Prevalent CVD 282 (5.1) 564 (14.1) <0.001
Serum lipid-reducing agent use 739 (13.3) 639 (16.0) 0.001
Current smoker 809 (14.5) 874 (21.9) <0.001
Total cholesterol, mmol/l 5.9 ± 0.9 5.5 ± 0.9 <0.001
Insulin, pmol/l 69.0 (30.0–182.0) 71.0 (30.0–188.0) 0.2
Glucose, mmol/l 5.3 (4.6–6.4) 5.5 (4.7–6.5) <0.001
Metabolic indices
BMI, kg/m2 27.1 ± 4.5 26.7 ± 3.4 <0.001
WC, cm 89.1 ± 11.8 97.7 ± 10.0 <0.001
HDL-cholesterol, mmol/l 1.5 (0.9–2.3) 1.2 (0.8–1.9) <0.001
TG, mmol/l 1.3 (0.7–2.8) 1.3 (0.7–3.1) <0.001
VAI 1.6 (0.6–4.8) 1.5 (0.6–4.8) 0.008
LAP 38.1 (11.4–106.8) 42.6 (15.7–122.4) <0.001
TyG 2.8 ± 0.5 2.9 ± 0.5 <0.001
DXA measurementsa
Android fat, % 3.3 (1.8–4.5) 3.1 (1.6–4.3) <0.001
Gynoid fat, % 6.3 (4.5–8.1) 3.9 (2.6–5.3) <0.001
Android to gynoid fat ratio, % 0.5 (0.3–0.7) 0.8 (0.5–1.1) <0.001
Total fat mass, % 39.3 (27.2–48.6) 27.6 (16.9–37.1) <0.001
Values are presented as means ± SD, median (interquartile range) or n (%)
a Of the 9564 participants, DXA measurements were available for 1770 women and 1258 men (n=3028). The
baseline characteristics of participants with DXA measurements differed significantly (p<0.001) from those of
participants without DXA measurements but were not significantly different for prevalent CVD (p=0.3), HDL-
cholesterol (p=0.055) and TG (p=0.7). However, given that they were in the same cohorts of the Rotterdam Study,
but had different visits, participants with DXA measurements included in the analyses are a subset of the study
sample without DXA measurements, who survived until the next Rotterdam Study visit, when DXA was
measured
p values are for the comparison of baseline characteristics between women and men
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In the analyses stratified for obesity status, per cent gynoid
fat (0.57; 0.38, 0.84) and the ratio of per cent android to
gynoid fat (1.77; 1.29, 2.41) remained significantly associated
with incident type 2 diabetes in the multivariable-adjusted
model (model 4) only in non-obese women (ESM Table 4).
After additionally adjusting for FPG (model 5), only the ratio
of per cent android to gynoid fat mass (1.51; 1.09, 2.08)
remained associated with incident type 2 diabetes in non-
obese women (ESM Table 4).
Discussion
In the large population-based Rotterdam Study, the novel met-
abolic indices VAI, LAP and TyG were stronger risk markers
for incident diabetes compared with traditional anthropomet-
ric and lipid measures among women. The magnitude of as-
sociation of these novel metabolic indices with diabetes was
comparable with that of DXA-measured body fat composi-
tions in women. Among men, neither combined metabolic
indices nor DXA measures of body fat were superior to tradi-
tional anthropometric and lipid measures, in particular BMI,
in association with diabetes.
VAT is a hormonally active component of total body fat,
which may play a key role in the association between adipos-
ity and glucose metabolism [4, 8–10]. Excess visceral adipos-
ity has been linked to a higher risk of type 2 diabetes, regard-
less of obesity [2, 3, 7, 12]. The three combined metabolic
indices VAI, LAP and TyG have been introduced as indicators
of ‘visceral adipose function’ [15] and insulin resistance
[18–20] and have been linked to cardiometabolic risk [15],
prediabetes [28] and diabetes [28] in cross-sectional studies.
Our study is the first to simultaneously investigate the longi-
tudinal associations of all these new indices, as well as their
components, with incident type 2 diabetes among women and
men. The three novel combined metabolic indices were all
independently associated with increased risk of diabetes in
our study. VAI and LAP combine both anthropometric and
metabolic variables to evaluate, respectively, adiposity dys-
function and lipid overaccumulation, whereas TyG includes
only metabolic variables. TyG is among the most mentioned
insulin resistance indices in the literature [29–36]. TyG has
also been suggested as a promising biomarker for glycaemic
control in people with type 2 diabetes [30], even better than
HOMA [29]. In comparison with FPG, TyG improved diabe-
tes risk prediction in individuals with normal FPG [37]. LAP
includesWC and TG, similarly to hypertriglyceridaemic waist
[17], and is an index of excessive lipid accumulation. Since
precise measurement of visceral fat content requires the use of
expensive imaging techniques such as CT or MRI [2, 12],
simple and economical quantification of these visceral adipos-
ity indices could lead to improvements in identification of
individuals at high risk of developing type 2 diabetes.
The counterbalance between insulin secretion and insulin
resistance is critical for type 2 diabetes pathogenesis. VAI,
LAP and TyG have been introduced as early indicators of
Table 2 Associations between different metabolic indices and incident
type 2 diabetes (N = 9564)
Index Incident type 2 diabetes HR (95% CI)
Women (511 cases) Men (388 cases)
BMI
Model 1 *1.51 (1.39, 1.63) *1.64 (1.45, 1.86)
Model 2 NA NA
Model 3 *1.49 (1.38, 1.62) *1.61 (1.42, 1.82)
Model 4 *1.37 (1.26, 1.49) *1.45 (1.28, 1.65)
Model 5 *1.27 (1.17, 1.38) *1.25 (1.09, 1.43)
WC
Model 1 *1.62 (1.49, 1.77) *1.44 (1.31, 1.58)
Model 2 *1.39 (1.19, 1.61) 1.15 (0.94, 1.39)
Model 3 *1.37 (1.18, 1.59) 1.13 (0.92, 1.38)
Model 4 *1.24 (1.07, 1.45) 1.04 (0.83, 1.31)
Model 5 1.04 (0.89, 1.22) 1.04 (0.82, 1.30)
1/HDLa
Model 1 *1.58 (1.44, 1.74) *1.53 (1.36, 1.73)
Model 2 *1.46 (1.33, 1.61) *1.42 (1.25, 1.61)
Model 3 *1.46 (1.32, 1.61) *1.40 (1.24, 1.59)
Model 4 *1.29 (1.14, 1.46) *1.32 (1.14, 1.52)
Model 5 *1.29 (1.14, 1.47) *1.41 (1.22, 1.63)
TGa
Model 1 *1.58 (1.44, 1.74) *1.44 (1.30, 1.58)
Model 2 *1.45 (1.31, 1.60) *1.30 (1.18, 1.45)
Model 3 *1.41 (1.28, 1.56) *1.28 (1.15, 1.42)
Model 4 *1.24 (1.10, 1.39) 1.12 (0.99, 1.27)
Model 5 1.07 (0.95, 1.21) 0.94 (0.83, 1.06)
VAIa
Model 1 *1.65 (1.51, 1.81) *1.52 (1.36, 1.69)
Model 2 NA NA
Model 3 *1.49 (1.35, 1.65) *1.37 (1.22, 1.53)
Model 4 *1.49 (1.36, 1.65) *1.37 (1.22, 1.53)
Model 5 *1.29 (1.17, 1.43) *1.23 (1.09, 1.38)
LAPa
Model 1 *1.83 (1.65, 2.03) *1.66 (1.47, 1.87)
Model 2 *1.60 (1.41, 1.82) *1.47 (1.27, 1.70)
Model 3 *1.55 (1.36, 1.76) *1.43 (1.24, 1.66)
Model 4 *1.35 (1.16, 1.56) *1.19 (1.01, 1.42)
Model 5 1.08 (0.93, 1.26) 0.96 (0.81, 1.15)
TyG
Model 1 *2.06 (1.86, 2.29) *1.74 (1.56, 1.94)
Model 2 *1.88 (1.69, 2.09) *1.58 (1.41, 1.77)
Model 3 *1.82 (1.64, 2.04) *1.55 (1.38, 1.75)
Model 4b *1.73 (1.52, 1.98) *1.43 (1.26, 1.62)
Model 5 NA NA
HRs are presented per 1 SD increase in the marker
Model 1, adjusted for age and cohort; model 2, additionally adjusted for
BMI; model 3, additionally adjusted for systolic BP, treatment for hyper-
tension, smoking and prevalent CVD; model 4, additionally adjusted for
HDL-cholesterol, TG and serum lipid-reducing agents; model 5, addi-
tionally adjusted for FPG
aMarker is loge transformed
b p value from the interaction test for the difference in HR between wom-
en and men <0.05
*p<0.05, by Cox proportional hazards model
NA, not applicable
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insulin resistance [18–20]. In our study, these three indices
were all moderately correlated with an index of insulin resis-
tance (HOMA-IR) and showed a smaller correlation with in-
sulin secretion (HOMA-B). As VAI and LAP combine both
lipid variables and adiposity status, they could serve as better
surrogates for insulin resistance compared with either lipid or
adiposity measures alone. The largest correlation of TyG with
insulin resistance in our study is in line with other study find-
ings, supporting a central role of both lipotoxicity and
glucotoxicity in modulating insulin resistance [38]. Since obe-
sity has a strong impact on dyslipidaemia, insulin resistance
and the development of type 2 diabetes, we further stratified
the analyses based on obesity status. Correlation of different
combined adiposity indices with HOMA measures did not
materially differ between non-obese and obese individuals.
The overall tendency towards stronger associations of these
metabolic indices with incident diabetes among non-obese
individuals might be due to their lower discriminatory power
among higher risk obese individuals.
While the exact mechanisms responsible for the relation-
ship between excess abdominal/visceral fat and cardiometa-
bolic risk are still unclear, several hypotheses have been pro-
posed [39–41]. Subcutaneous fat faces obesogenic stress with
a limited capacity for regional adipocyte hypertrophy or hy-
perplasia. Once this capacity is surpassed, adipose tissue stor-
age is forced into other regions, such as organs or compart-
ments of the body, termed ectopic. Visceral fat is considered
the classic ectopic fat depot and is associated with dysfunc-
tional adiposity or adiposopathy [42, 43].
In our study, WC, TG, VAI, LAP and TyG showed a stron-
ger association with incident type 2 diabetes among women
compared with men. Similarly, the correlations between VAI,
LAP and TyGwith HOMA-IR in our study were overall stron-
ger among women. The greater association of VAT with dia-
betes and adverse cardiovascular risk profiles among women
has been suggested in several studies [44, 45]. Sex differences
in adverse metabolic outcomes associated with visceral fat
have been related to a significantly lower visceral fat area in
non-diabetic women compared with non-diabetic men, and a
similar visceral fat area for both diabetic women andmen [44].
Among individuals with more visceral fat, a greater portion of
hepatic NEFA delivery originates from VAT lipolysis [46].
Contribution of visceral lipolysis to hepatic NEFA delivery
in relation to visceral fat has been found to be greater in wom-
en than in men [46]. Moreover, correlation between VAT area
and serum TG has been found to be stronger in women than in
men [47].
No previous study has investigated the associations of
DXA measures of body fat with incident type 2 diabetes.
Our study suggests that per cent gynoid fat and per cent an-
droid to gynoid fat ratio among women and total fat mass
among men are independent risk markers for diabetes.
Previous studies have shown important relations between an-
droid to gynoid fat ratio and metabolic risk in healthy adults.
Android or truncal obesity has been associated with the risk of
metabolic disorders and CVD [48], yet there is evidence that
gynoid fat distribution may be protective [49]. Android fat
depot is the adipose tissue mainly around the trunk including,
but not exclusively, visceral fat. Compared with abdominal
visceral fat, android fat depot has shown a larger association
with the metabolic syndrome in elderly people [5]. In line with
our findings, high per cent android to gynoid fat ratio has
shown a larger correlation with cardiometabolic dysregulation
compared with per cent android fat, per cent gynoid fat or
BMI [13]. Compared with women with a predominantly
Table 3 Associations between DXA measurements of body fat and
incident type 2 diabetes (N = 3028)
DXA measurement Incident type 2 diabetes HR (95% CI)
Women (185 cases) Men (137 cases)
Android fat mass, %a
Model 1 *1.77 (1.42, 2.22) *1.43 (1.13, 1.81)
Model 2 *1.42 (1.06, 1.89) *1.44 (1.06, 1.95)
Model 3 *1.36 (1.02, 1.82) *1.41 (1.04, 1.92)
Model 4 1.22 (0.91, 1.64) 1.32 (0.96, 1.83)
Model 5 1.10 (0.83, 1.46) 1.33 (0.96, 1.85)
Gynoid fat mass, %a
Model 1 1.01 (0.76, 1.35) 1.21 (0.91, 1.59)
Model 2 *0.56 (0.40, 0.78) 1.03 (0.74, 1.44)
Model 3 *0.57 (0.41, 0.79) 1.03 (0.74, 1.44)
Model 4b *0.63 (0.45, 0.89) 1.12 (0.78, 1.59)
Model 5 0.76 (0.54, 1.07) 1.08 (0.76, 1.55)
Android to gynoid fat ratioa
Model 1 *1.95 (1.55, 2.46) *1.56 (1.16, 2.11)
Model 2 *1.73 (1.36, 2.22) *1.49 (1.09, 2.04)
Model 3 *1.69 (1.32, 2.17) *1.46 (1.06, 1.99)
Model 4 *1.51 (1.16, 1.97) 1.26 (0.91, 1.76)
Model 5 1.28 (0.98, 1.67) 1.32 (0.93, 1.88)
Total fat mass, %a
Model 1 *1.56 (1.17, 2.08) *1.43 (1.11, 1.84)
Model 2 0.77 (0.53, 1.11) *1.43 (1.00, 2.04)
Model 3 0.75 (0.52, 1.08) 1.41 (0.98, 2.02)
Model 4b 0.76 (0.52, 1.13) 1.45 (0.99, 2.12)
Model 5 0.86 (0.59, 1.26) 1.45 (0.99, 2.12)
HRs are presented per 1 SD increase in the marker
Model 1, adjusted for age and cohort; model 2, additionally adjusted for
BMI; model 3, additionally adjusted for systolic BP, treatment for hyper-
tension, smoking and prevalent CVD; model 4, additionally adjusted for
HDL-cholesterol, TG and serum lipid-reducing agents; model 5, addi-
tionally adjusted for FPG
aMarker is loge transformed
b p value from the interaction test for the difference in HR between wom-
en and men <0.05
*p<0.05, by Cox proportional hazards model
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gynoid fat distribution, android obesity in women has been
correlated with a higher incidence of glucose intolerance [50].
Excess android fat mass has recently been associated with
high TG and low HDL-cholesterol levels in men and high
LDL- and low HDL-cholesterol levels in women. Excess
gynoid fat mass has been positively correlated with total cho-
lesterol in men and has shown a favourable association with
TG and HDL-cholesterol in women [51]. Increased gynoid fat
mass has also been shown to be protective against the progres-
sion of non-alcoholic fatty liver disease in Japanese women
with type 2 diabetes [52]. It therefore seems that regional fat
distribution in the android and gynoid regions have varying
effects on lipid profiles among women and men. In line with
this, we found an inverse association in women between
gynoid fat and android to gynoid fat ratio and type 2 diabetes
and a positive association in men between total fat mass and
type 2 diabetes.
In our study, the magnitude of association between DXA
measures of body fat and diabetes was comparable with that of
combined metabolic indices and traditional anthropometric
and lipid measures. Considering the costs and radiation expo-
sure associated with DXA measurement, its use in the general
population as a screening tool for diabetes may therefore not
be justified, and using well-established and simple anthropo-
metric variables such as BMI might suffice.
To our knowledge, this is the first prospective population-
based cohort study to simultaneously investigate the associa-
tions between novel metabolic indices as well as DXA mea-
sures with incident diabetes among women and men over a
long follow-up period.We used data from a well-characterised
prospective cohort study, which allowed for direct comparison
of several metabolic indices as well as correction for a wide
range of covariates.
The limitations of our study also warrant attention. Our
population comprised individuals aged 45 years and older of
European ancestry. One might speculate that the impact of
VAT on diabetes incidence would have been even stronger in
a younger population. Thus, generalisation of our results to
younger age groups and other ethnicities should be made with
caution.Moreover, as with other cohort studies, the possibility
of selection bias could not be entirely ruled out. Due to the
unavailability of CT or MRI in our population, visceral adi-
posity was not directly measured but estimated. Also, we did
not have DXA measures specifically for visceral fat in the
Rotterdam Study. Instead, android fat measured by DXA
was used as a proxy for visceral fat. Thus, comparison of
our results against the gold standard measures for visceral fat
is not possible. We did not include variables such as socioeco-
nomic status, family history of diabetes, dietary intake and
physical activity in our multivariable models, as they were
not available.
In conclusion, the novel combined metabolic indices VAI,
LAP and TyG were stronger risk markers for incident type 2
diabetes compared with traditional anthropometric and lipid
measures among women. The predictive value of these novel
metabolic indices for type 2 diabetes was also comparable
with that of DXA-measured body fat compositions in women.
Neither combined metabolic indices nor DXA measures of
body fat were superior to traditional anthropometric and lipid
measures in association with type 2 diabetes among men. In
particular, BMI remained the best marker for type 2 diabetes
risk in men and among the best markers in women. BMI could
therefore be used as a simple and useful tool for diabetes risk
screening in the general population.
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